Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
Annals of Internal Medicine · 2023-03 · 176 (3)
DOI: 10.7326/l22-0490 ↗Kurz gefasst
Leserbrief in der Zeitschrift Annals of Internal Medicine, 2023-03. Verfasst von Lisa M DeTora und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hofstra University, Hempstead, New York. Hauptthemen laut MEDLINE: Biomedical Research. Die Arbeit wurde bisher 14-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hofstra University, Hempstead, New York.
- City University of Hong Kong, Hong Kong, China.
- Pfizer, New York, New York.
- Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland.
- Merck, Boston, Massachusetts.
- New York Medical College, Valhalla, New York.
ORCID-Profile: Lisa M DeTora, Trevor Lane, Angela Sykes, Faith DiBiasi, Dikran Toroser, Leslie Citrome
Zitieren
APA
DeTora, L. M., Lane, T., Sykes, A., DiBiasi, F., Toroser, D., & Citrome, L. (2023). Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine, 176(3). https://doi.org/10.7326/l22-0490
Vancouver
DeTora LM, Lane T, Sykes A, DiBiasi F, Toroser D, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2023;176(3). doi:10.7326/l22-0490
BibTeX
@article{DeTora2023,
author = {DeTora, Lisa M and Lane, Trevor and Sykes, Angela and DiBiasi, Faith and Toroser, Dikran and Citrome, Leslie},
title = {Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update},
journal = {Annals of Internal Medicine},
year = {2023},
volume = {176},
number = {3},
doi = {10.7326/l22-0490}
}
EUVIMED